Edition:
India

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

78.27CNY
21 Jun 2018
Change (% chg)

¥-0.67 (-0.85%)
Prev Close
¥78.94
Open
¥78.94
Day's High
¥79.92
Day's Low
¥77.18
Volume
21,929,839
Avg. Vol
17,866,615
52-wk High
¥83.29
52-wk Low
¥37.24

Latest Key Developments (Source: Significant Developments)

Jiangsu Hengrui Medicine passes FDA approval
Monday, 21 May 2018 

May 21(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received approval for fondaparinux sodium injection (product) from U.S Food and Drug Administration .Company will be able to sell the product in the U.S. after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine passes FDA approval
Thursday, 10 May 2018 

May 10 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received approval for its drug Thiotepa for injection, which is used for treatment of breast cancer, ovarian cancer and other lymphoma, from U.S Food and Drug Administration .  Full Article

Jiangsu Hengrui Medicine announces 2017 dividend payment
Monday, 16 Apr 2018 

April 16(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it plans to pay cash dividend of 1.30 yuan per 10 shares (before tax), distribute two new shares for every 10 shares as stock dividends, and use additional paid-in capital to distribute one new share for every 10 shares, as the dividend payment plan for 2017.  Full Article

Jiangsu Hengrui Medicine to invest 610.7 mln yuan in medical firm
Monday, 16 Apr 2018 

April 16(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it plans to invest 610.7 million yuan in a Chengdu-based medical firm, and will increase stake in the medical firm to 95.9 percent from 84 percent .  Full Article

Jiangsu Hengrui Medicine announces change in accounting policy
Monday, 16 Apr 2018 

April 16(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it changes accounting policy based on accounting standards for business enterprises.  Full Article

Jiangsu Hengrui Medicine's 2017 Net Profit Up 24.25 Pct Y/Y
Sunday, 15 Apr 2018 

April 15 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS 2017 NET PROFIT UP 24.25 PERCENT Y/Y AT 3.22 BILLION YUAN ($513.35 million).  Full Article

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

Jiangsu Hengrui Medicine says license agreement on JAK1 inhibitor SHR0302 with U.S.-based firm Arcutis
Friday, 5 Jan 2018 

Jan 5(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says co signs license agreement with U.S.-based firm Arcutis regarding JAK1 inhibitor SHR0302 .Says co grants Arcutis an exclusive right to develop and sell JAK1 inhibitor SHR0302 in United States of America, European Union and Japan.Says co will receive upfront and milestones payment of up to $223 million and sales commissions from Arcutis.  Full Article

Jiangsu Hengrui Medicine passes U.S. FDA approval
Wednesday, 29 Nov 2017 

Nov 29(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration.Company will be able to sell its Dexmedetomidine Hydrochloride Injection in the United States after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine gets approval for clinical trials of drugs
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration.  Full Article

BRIEF-Jiangsu Hengrui Medicine unit passes U.S. FDA approval

* Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration